When was chlordiazepoxide approved by the FDA, and what was it for?
Chlordiazepoxide (brand name Librium) was approved by the U.S. FDA in 1960 as the first benzodiazepine. It was introduced as a treatment for conditions such as anxiety and related agitation, with dosing and specific indications defined by the FDA labeling at the time.
Why is 1960 often mentioned in connection with FDA approval?
“1960” is used because that is the year FDA approval was granted for chlordiazepoxide, marking an early shift in prescription options for anxiety away from older sedatives and toward benzodiazepines.
What happened after FDA approval in 1960?
After approval, chlordiazepoxide became widely used and helped establish benzodiazepines as a major class of anti-anxiety and sedative medicines. Other benzodiazepines followed later, but the 1960 approval is commonly cited as the starting point for FDA-approved benzodiazepines in the U.S.
What should patients or clinicians know about the approval era?
Benzodiazepines were approved and used before many of today’s modern risk-management approaches (such as boxed warnings and tighter restrictions). Current prescribing and safety monitoring practices for benzodiazepines reflect later evidence about dependence, withdrawal, sedation, and interaction risks with other central nervous system depressants.
Where to verify the exact FDA approval date and original label wording
For the most precise “approval date” and the initial indication language, the best sources are FDA drug-approval records and historical labeling for Librium/chlordiazepoxide.
Sources
I don’t have the provided documents or a live FDA database in this chat, so I can’t cite a specific FDA approval record or exact day/month—only the year (1960). If you share a link or the FDA record text you’re working from, I can extract the exact approval date and the original approved indications and wording.